Effects of the Anion Type and the Time of Administration of Lithium Salts on the Circadian Dynamics of Lithium Urinary Excretion in Rats

Introduction: Dulaglutide (Trulicity â) is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist indicated in adults with type 2 diabetes mellitus. Data about the safety profile of dulaglutide are lacking due to the lack of experience with this recently marketed drug. Material and methods: We report the first case of a beneficial effect of dulaglu-tide. Results: A 48-year-old woman with hypertension, cardiac insufficiency and depression was treated with amlodipine, valsartan, spironolactone, nebivolol, atorvastatine, esomeprazole, escitalopram, oxazepam and tramadol. She had lower limb edema since a lot of months. For diabetes mellitus, dulaglutide (1.5 mg once a week) was started and the lower limb edema began to improve. Three months later, the lower limb edema has disappeared without any new treatment. The dulaglutide had to be interrupted for 2 months and edema recurred. The use of hydrochlorothiazide (25 mg/day) had no effect but the lower limb edema disappeared again after dulaglutide was resumed while all the other drugs were maintained. Discussion/Conclusion: The temporal relationship between dulaglutide treatment and regression of the edema is in favour of the role of dulaglutide and the role of the other drugs, continuously maintained, is ruled out. No regression of edema had been previously reported with dulaglutide. However, animal studies suggest that GLP-1 or its agonists have diuretic and natriuretic effects, which are mediated by an increase in renal plasma flow and glomerular filtration rate, as well as a decrease in the proximal reabsorption of sodium with an increase in fractional sodium excretion [1,2]. Moreover, GLP-1 reduced Na + /H + exchanger isoform 3 (NHE3)-mediated bicarbonate reabsorption in the renal proximal tubule, resulting in a decrease of sodium, bicarbonate and water reabsorption. A study in humans concluded that liraglutide, another GLP-1 agonist, decreases the proximal tubular sodium reabsorption, but has no effect on glomerular filtration rate or renal blood flow [3]. Thus, the GLP-1 agonists and especially dulaglutide could probably have a potential interest in disorders of sodium retention. References [1] Crajoinas RO et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am. [3] Skov J et al. Short-term effects of liraglutide on kidney function and vasoac-tive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes. Metab. (2016) 18: 581-589. PS1-002 A comparative study of QT prolongation with Serotonin Reuptake Inhibitors (SRIs) A Senard-Ojedo, L Chebane, M Araujo, V Rousseau, F Montastruc, JL Montastruc Laboratoire de Pharmacologie M edicale et Clinique, Centre Midi-Pyr en ees de PharmacoVigilance, de Pharmaco epid emiologie et d'Informations sur le M edicament, Pharmacop^ ole Midi-Pyr en ees, INSERM UMR 1027, CHU et Facult e de M edecine-Toulouse (France) Introduction: QT interval prolongations were described with citalopram or esci-talopram. However, the effects of the other SRIs remai...

show abstract

“…To achieve stable serum lithium concentration, rats were i.m. injected 5 mg/kg of LiCl daily for 1 week before the experiments .…”

Section: Methodsmentioning

confidence: 99%

Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon‐Like Peptide‐1

Kutina

Golosova

Marina

et al. 2016

J Neuroendocrinology

View full text Add to dashboard Cite

show abstract

Effects of the Anion Type and the Time of Administration of Lithium Salts on the Circadian Dynamics of Lithium Urinary Excretion in Rats

Cited by 1 publication

References 3 publications

Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon‐Like Peptide‐1

Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon‐Like Peptide‐1

Contact Info

Product

Resources

About